Novo Nordisk Ends Hims & Hers Deal Over Wegovy Sales
Novo Nordisk has ended its partnership with U.S. telehealth firm Hims & Hers Health regarding the sale of its blockbuster obesity drug Wegovy. The online health platform gained access to sell the drug through a bundled package after the companies announced their partnership in April.
Novo made this decision after Hims declared it would maintain its distribution of Wegovy personalized doses through clinical need exceptions. The distribution practices of Hims have raised doubts among analysts about their compliance with legal requirements and Novo's willingness to accept these practices because of its broader concerns about off-label compounding. The company markets both liraglutide which is an older generic from Novo and Zepbound which is an obesity drug from Eli Lilly.
The Danish drugmaker confirmed its dedication to distribute FDA-approved Wegovy through specific telehealth providers who meet safety and regulatory requirements. The FDA gained authority to remove semaglutide from its shortage list after a recent U.S. court decision which restricted operations of compounding pharmacies.
The premarket trading session showed Hims & Hers stock value decreasing by 22% while Novo stock prices dropped more than 6% during early European trading hours.
Dominic Maley is an American journalist recognized for his sharp and insightful reporting on social and political issues. His work is known for its depth, integrity, and the ability to highlight critical societal concerns.